Clinical Research Directory
Browse clinical research sites, groups, and studies.
Impact of Implementation Strategies on Lp(a) Testing in Secondary Care Settings
Sponsor: Novartis Pharmaceuticals
Summary
Lipoprotein(a) \[Lp(a)\] is recognised as an independent, non-modifiable genetic risk factor for cardiovascular (CV) disease. Current guidelines from the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) recommend that Lp(a) be measured at least once in every adult's lifetime, however routine Lp(a) testing rates remains infrequent. The aim of this study is to assess the impact of implementation strategies (IStr) designed to increase the adoption of Lp(a) testing in routine practice, ultimately leading to more individuals being tested in secondary care. This, in turn, is expected to result in the identification and enhanced management of Cardiovascular Disease (CVD) risk patients with elevated Lp(a).
Official title: Lp(a)CCELERATE: Impact of Implementation Strategies on Lp(a) Testing in Secondary Care Settings
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
4500
Start Date
2025-11-28
Completion Date
2028-03-31
Last Updated
2026-04-02
Healthy Volunteers
No
Locations (1)
Novartis Investigative Site
Nuremberg, Germany